Found this article from The Prostate Cancer Newsletter very interesting. In case you do not subscribe to or you missed it, this is great news for future treatment.
This is the 3rd posting of that article. Perhaps three were needed to get me to respond:
""We are hoping to develop both this (R)-9b drug and NXTAR into new therapies for prostate cancer patients who have developed resistance to the front-line treatments," Mahajan said."
Doesn't that strike you as odd? It's a therapy for CRPC? Can't it be used to prevent CRPC?
WOW! Thanks for sharing. Another big move to delay ADT Hormone Resistance. EXTEND LIFE!!Moffit Cancer Center in Tampa has applied for a patent,The (R)-9b inhibitor has been licensed to a biotechnology startup company called TechnoGenesys. Mahajan and co-author Kiran Mahajan are co-founders of the company. They also own stock and serve as consultants to TechnoGenesys.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.